Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan

Masayuki Shiba1,2, Takao Kato2,3*, Moritoshi Funasako2, Eisaku Nakane2, Shoichi Miyamoto2, Toshiaki Izumi2, Tetsuya Haruna2, Moriaki Inoko2

1 Department of Cardiovascular Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan, 2 Cardiovascular Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan, 3 Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

* tkato75@kuhp.kyoto-u.ac.jp

Abstract

Background
Psoriasis vulgaris is a chronic inflammatory skin disease with an immune-genetic background. It has been reported as an independent risk factor for coronary heart disease (CHD) in the United States and Europe. The purpose of this study was to investigate the association between psoriasis and CHD in a hospital-based population in Japan.

Methods
For 113,065 in-hospital and clinic patients at our institution between January 1, 2011 and January 1, 2013, the diagnostic International Classification of Diseases (ICD)-10 codes for CHD, hypertension, dyslipidemia, diabetes, and psoriasis vulgaris were extracted using the medical accounting system and electronic medical record, and were analyzed.

Results
The prevalence of CHD (n = 5,167, 4.5%), hypertension (n = 16,476, 14.5%), dyslipidemia (n = 9,236, 8.1%), diabetes mellitus (n = 11,555, 10.2%), and psoriasis vulgaris (n = 1,197, 1.1%) were identified. The prevalence of CHD in patients with hypertension, dyslipidemia, diabetes, and psoriasis vulgaris were 21.3%, 22.2%, 21.1%, and 9.0%, respectively. In 1,197 psoriasis patients, those with CHD were older, more likely to be male, and had more number of the diseases surveyed by ICD-10 codes. Multivariate analysis showed that psoriasis vulgaris was an independent associated factor for CHD (adjusted odds ratio [OR]: 1.27; 95% confidence interval [CI]: 1.01–1.58; p = 0.0404) along with hypertension (adjusted OR: 7.78; 95% CI: 7.25–8.36; p < 0.0001), dyslipidemia (adjusted OR: 2.35; 95% CI: 2.19–2.52; p < 0.0001), and diabetes (adjusted OR: 2.86; 95% CI: 2.67–3.06; p < 0.0001).

Conclusion
Psoriasis vulgaris was independently associated with CHD in a hospital-based population in Japan.
Introduction

Psoriasis vulgaris is a chronic inflammatory skin disease with an immune-genetic background. Although its pathogenesis is not fully understood, there is solid evidence of a susceptibility locus in the human leukocyte antigen region [1, 2]. Genetic polymorphisms in the vascular endothelial growth factor (VEGF) gene may also contribute to psoriasis and differ between Caucasians and Asians [3]. Psoriasis is common in Caucasians but is rare in Africans [4, 5]. In Asians, psoriasis is less common. The prevalence of psoriasis vulgaris is 0.34% of the general population in Japan [6]. This prevalence is lower than that of the general population in the United States and Europe (2.0–4.0%) [7–9].

Systemic low-grade inflammation may be involved in the pathogenesis of psoriasis [10, 11]. Patients with psoriasis vulgaris typically have a higher prevalence of dyslipidemia, hypertension, smoking, and obesity compared to those without psoriasis [12]. These comorbidities overlap with the risk factors of coronary heart disease (CHD) [12–15], although the precise mediated mechanisms linking psoriasis and CHD have not been clear.

Many studies in the United States and Europe have shown that psoriasis is an independent risk factor for CHD and cardiovascular events [16–24] or cardiovascular mortality [25]; however, in contrast, other studies concluded that psoriasis is not an independent risk factor for coronary atherosclerosis and acute cardiovascular events [26–30]. These conflicting results may be because of the differences in the study design, severity of psoriasis, or confounders and effect modifiers, such as psoriatic arthritis [31]. In Japan, the relationship between psoriasis vulgaris and CHD has almost never been studied. One reason for this is the rarity of psoriasis vulgaris in Japanese patients [6]. Considering that an immune-genetic background strongly affects the prevalence of psoriasis and the common underlying causes such as systemic low-grade inflammation, the association between psoriasis and CHD should also be apparent in Japanese patients. The aims of this study were to investigate the relationship between psoriasis vulgaris and CHD in a hospital-based population in Japan.

Methods

Patient population

The medical accounting system and electronic medical record (EMR) data of all clinic and in-hospital patients of all ages at our institution between January 1, 2011 and January 1, 2013 were studied retrospectively. From the EMR data, we extracted patients’ data, including their name, age, and sex by each disease, i.e., psoriasis vulgaris (International Classification of Diseases [ICD]-10 code L40.0), hypertension (ICD-10 codes I10, I11, I12, I13, I14, and I15), dyslipidemia (ICD-10 code E78), diabetes mellitus (ICD-10 codes E10, E11, E12, E13, and E14), and CHD. CHD included ischemic heart disease, myocardial infarction (acute, sub-acute, or old, i.e., ICD-10 codes I21, I22, and I25.2, respectively), and angina pectoris (I20). Each disease was regarded as present when the diagnoses were recorded in the hospital charts. The total number of in-hospital and clinic patients at our institution was determined by the medical accounting system. The research protocol was approved by the institutional review board of Kitano Hospital according to the ethical guidelines of the 1975 Declaration of Helsinki (P15-06-005). Since this is a retrospective study, the consent was not obtained and patient records/information was anonymized and de-identified prior to analysis.

Statistics

Continuous variables are expressed as the mean ± standard deviation. Mean numbers of risk factors are expressed as the mean and 95% confidence interval (CI). In comparisons of the baseline characteristics of the study population, the chi square test was used for categorical
variables and the Wilcoxon rank sum test was used for continuous variables when appropriate. Differences in categorical variables among two or more groups were analyzed using the Cochran-Mantel-Haenszel test. Associations between the diseases surveyed and CHD in patients overall were analyzed using a multivariate logistic regression model, which was adjusted for hypertension, dyslipidemia, diabetes mellitus, and psoriasis. In subgroup analysis of patients who had at least one disease, including CHD, hypertension, dyslipidemia, diabetes, and psoriasis, the association between factors were analyzed by using a multivariate logistic regression model, which was adjusted for hypertension, dyslipidemia, diabetes mellitus, psoriasis, and sex as categorical variables and age as a continuous variable. Adjusted odds ratios (ORs) and 95% CIs were calculated. A p value <0.05 was considered statistically significant in all analyses. Statistical analyses were performed using JMP software, version 10 (SAS Corp.).

Results

The prevalence of CHD (n = 5,167, 4.2%), hypertension (n = 16,476, 14.5%), dyslipidemia (n = 9,236, 8.1%), diabetes mellitus (n = 11,555, 10.2%), and psoriasis vulgaris (n = 1,197, 1.0%) were identified (Table 1). The prevalence of CHD in patients with hypertension, dyslipidemia, diabetes, and psoriasis vulgaris were 21.3% (3,510/16,476), 22.2% (2,056/9,236), 21.1% (2,442/11,555), and 9.0% (108/1197), respectively (Table 1).

Regardless of whether patients did or did not have psoriasis, patients with CHD had more number of the three major diseases (hypertension, dyslipidemia, and diabetes) related to CHD than those without CHD (p < 0.001, Table 2). In 1,197 psoriasis patients, those with CHD were older and more likely to be male than those without CHD (p < 0.001), and they had the highest number of the above-mentioned diseases than the other groups (p < 0.001 by the Cochran-Mantel-Haenszel test, Table 2).

Multivariate logistic regression analysis after adjusting for hypertension, dyslipidemia, and diabetes, and psoriasis, showed that psoriasis vulgaris was still independently associated with CHD (adjusted OR: 1.27; 95% CI: 1.01–1.58; p = 0.0404), along with hypertension (adjusted OR: 7.78; 95% CI: 7.25–8.36; p < 0.0001), dyslipidemia (adjusted OR: 2.35; 95% CI: 2.19–2.52;

Table 1. Factors related to coronary heart disease (CHD) among the study patients.

| Variables                | Total (n = 113,065) | Present (n = 5167) | Absent (n = 107,898) |
|--------------------------|---------------------|--------------------|----------------------|
| With hypertension        |                     |                    |                      |
| Mean age (SD)            | 16,476 (14.5%)      | 3,510 (21.3%)      | 12,966 (78.7%)       |
|                          | 70.7 (14.3)         | 75.6 (11.0)        | 69.4 (14.8)          |
| Male (n, %)              | 8,642 (52.4%)       | 2,165 (61.8%)      | 6,477 (49.9%)        |
| With dyslipidemia        |                     |                    |                      |
| Mean age (SD)            | 9,236 (8.1%)        | 2,056 (22.2%)      | 7,180 (77.7%)        |
|                          | 70.0 (3.4)          | 75.3 (10.6)        | 68.5 (13.7)          |
| Male (n, %)              | 4,293 (46.1%)       | 1,211 (58.9%)      | 3,082 (42.9)         |
| With diabetes mellitus   |                     |                    |                      |
| Mean age (SD)            | 11,555 (10.2%)      | 2,442 (21.1%)      | 9,113 (78.9%)        |
|                          | 69.7 (13.2)         | 74.9 (10.3)        | 68.3 (13.5)          |
| Male (n, %)              | 6,741 (58.3%)       | 1,602 (65.6)       | 5,139 (56.3)         |
| With psoriasis           |                     |                    |                      |
| Mean age (SD)            | 1,197 (1.0%)        | 108 (9.0%)         | 1,089 (91.0%)        |
|                          | 64.9 (18.1)         | 75.0 (12.8)        | 63.1 (19.0)          |
| Male (n, %)              | 762 (63.6%)         | 81 (75.0%)         | 681 (62.5%)          |
| With CHD                 |                     |                    |                      |
| Mean age (SD)            | 5,167 (4.2%)        | 74.0 (12.0)        |                      |
| Male (n, %)              | 3,059 (59.2%)       |                    |                      |

doi:10.1371/journal.pone.0149316.t001
p < 0.0001) and diabetes (adjusted OR: 2.86; 95% CI: 2.67–3.06; p < 0.0001) in an entire hospital-based population (Fig 1). We next assessed 25,799 patients who have at least one disease including CHD, hypertension, dyslipidemia, diabetes, and psoriasis (Table A in S1 File). The psoriasis also shows an independent association with CHD after adjustment for sex and age (Table B in S1 File) in these patients.

Discussion

In this retrospective study, we showed the prevalence of psoriasis vulgaris in a hospital-based population in Japan. We also determined that psoriasis vulgaris is independently associated with CHD in these patients.

Table 2. Comparison of the characteristics in psoriasis patients with and without CHD.

| Variable | Present (n = 1,089) | Absent (n = 1,089) | Present (n = 111,868) | Absent (n = 106,809) |
|----------|--------------------|--------------------|-----------------------|----------------------|
| Age (y.o., mean, SD) | 64.1 ± 18.9 | 75.0 ± 12.8 | 63.1 ± 19.0 | n/a | 74.0 ± 12.0 | n/a |
| Male (n, %) | 762 (63.6%) | 81 (75%) | 681 (62.5%) | n/a | 2978 (58.8%) | n/a |
| Hypertension | 288 (24.0%) | 81 (75.0%) | 207 (19.0%) | 16,188 (14.4%) | 3,429 (67.7%) | 12,759 (11.9%) |
| Dyslipidemia | 231 (19.2%) | 63 (58.3%) | 168 (15.4%) | 9,005 (8.0%) | 1,993 (39.3%) | 7,012 (6.5%) |
| Diabetes mellitus | 252 (21.0%) | 60 (55.5%) | 192 (17.6%) | 11,303 (10.1%) | 2,382 (47.0%) | 8,921 (8.3%) |
| No. of the three major diseases* | 3 | 73 (6.1%) | 27 (25.0%) | 46 (4.2%) | 2,883 (2.5%) | 1,066 (21.0%) | 1,817 (1.7%) |
| | 2 | 173 (14.5%) | 49 (45.4%) | 124 (11.4%) | 7,112 (6.3%) | 1,594 (31.5%) | 5,518 (5.1%) |
| | 1 | 204 (17.0%) | 25 (23.1%) | 179 (16.5%) | 13,623 (12.1%) | 1,418 (28.0%) | 12,205 (11.4%) |
| | 0 | 747 (62.3%) | 7 (6.5%) | 740 (68.0%) | 88,250 (78.8%) | 981 (19.3%) | 87,269 (81.7%) |
| Mean No. of the disease† (95% CI) | 0.644 (0.590–0.697) | 1.888 (1.725–2.052) | 0.520 (0.469–0.571) | 0.326 (0.322–0.330) | 1.542 (1.524–1.560) | 0.268 (0.264–0.272) |

*: hypertension, dyslipidemia, and diabetes mellitus, CI: confidence interval, n/a: not available.

doi:10.1371/journal.pone.0149316.t002

Fig 1. Multivariate logistic regression analysis of the factors related to coronary heart disease. Data are adjusted for hypertension, dyslipidemia, diabetes mellitus, and psoriasis.

doi:10.1371/journal.pone.0149316.g001
Psoriasis has been associated with chronic systemic inflammation mediated by the type 1 helper T (Th1) cell [32, 33] and Th17 cell [10, 34, 35]. The Th1 cell stimulates macrophages that secrete tumor necrosis factor α (TNF-α). Recently, there has been an increasing interest in the Th 17 cell pathway [36] and related pro-inflammatory cytokines in psoriasis, including interleukin (IL)-17 and IL23 [37], which induce the production of inflammatory mediators such as IL1, IL6, IL8, and TNF-α [33]. TNF-α activates endothelium and facilitates leukocyte invasion into surrounding tissues, resulting in the formation of infiltrated plaques, and causes insulin resistance in endothelial cells through the p38 mitogen-activated protein kinase pathway [38]. Chronic inflammation is associated with insulin resistance, which leads to endothelial dysfunction by disturbing vasodilation through the endothelial nitric oxide synthase pathway [39]. The contribution of genetic polymorphisms to the VEGF gene in psoriasis has also been reported [3]. These data support the association between psoriasis and CHD through chronic low-grade systemic inflammation and endothelial dysfunction via the overlapping risks for CHD, as also shown in Japanese patients in the present study.

Psoriasis vulgaris has been reported to be independent risk factors for CHD in Europe and United States [16–24]. However, a recently published study by Parisi (2015), including a cohort of 48,523 patients with psoriasis and 208,187 controls and a greater number of predictor variables, did not find an association between psoriasis (hazard ratio [HR]: 1.02, 95%CI: 0.96–1.08) or severe psoriasis (HR:1.29, 95%CI: 0.97–1.70) and the risk for cardiovascular events [30]. In contrast, Dregan et al. (2014), using the same database and inception cohort design, found an independent association between psoriasis and coronary heart disease; their point estimate of the HR of coronary heart disease in severe psoriasis was 1.29 (95% CI: 1.01–1.64, p = 0.042). [23]. Ogdie also reported, using similar database, that the risk of cardiovascular events was higher in patients with psoriasis not prescribed a disease modifying anti-rheumatic drug (HR 1.08, 95%CI: 1.02–1.15) and in patients with severe psoriasis (disease modifying anti-rheumatic drug users: HR 1.42, 95%CI: 1.17–1.73) [40]. One reason for these conflicting results may be the inclusion of psoriatic arthritis as an independent confounder in the Parisi study [30,31]. Psoriatic arthritis is associated with psoriasis vulgaris; hence, it can be considered an effect modifying factor that moderates the relationship between psoriasis and outcome [31]. When psoriatic arthritis excluded, the fully adjusted HR of psoriasis and severe psoriasis was 1.46 (95%CI: 1.11–1.92) [30]. A possible association between severe psoriasis and cardiovascular disease was reported by a systematic review of 14 epidemiologic studies [41]. However, whether cardiovascular disease is directly associated with psoriasis remains uncertain, as many of these studies, as well as our present study, could not exclude the possibility of inadequate adjustment for risk factors [41].

Another reason for this inconsistency may be the study design (inception or prevalent cohort). An inception cohort fully captures risk in case of early disease-related outcomes. However, in the setting of psoriasis and CV risk, disease duration (and thus long-term exposure to inflammation) is related to the outcome, with increased risk of the poor outcome as the duration increases. [17]. Thus, use of an inception cohort with short-term follow-up will result in underestimation of the true effect. The prevalent cohort, in contrast, better represents psoriasis patients in the general population. Prevalent designs, however, also have limitations. [31]. The prevalent designs may lead to underestimation of the effect through exclusion of outcomes related to mortality (as in the cases of death from cardiovascular events). [23,40]. Our study design is cross-sectional with one time-point observation. The cardiovascular outcomes were not evaluated but the presence of CHD was assessed with psoriasis in the present study; hence we only addressed the independent association (adjusted OR: 1.27; 95% CI: 1.01–1.58; p = 0.0404).

There have been reports that the long-term use of anti-hypertensive drugs and hypertension itself are possibly associated with the development of psoriasis vulgaris [15,39,42].
Dyslipidemia has been also closely associated with psoriasis [43], although the mechanism of connections between psoriasis vulgaris and dyslipidemia is not clear. In another report which analyzed Japanese psoriasis patients, the prevalence of hyperlipidemia and hypertension ranged from 16.7% to 20.7% and from 22.8 to 28.5%, respectively [6], which is consistent with the prevalence in our analysis (Table 2). Table 3 shows the ORs of CHD reported previously in general or hospital-based population in Japan and other countries [17, 44–46]. ORs for CHD in this study were comparable for diabetes mellitus and dyslipidemia but seemed to be high for hypertension compared to those of the general population. The prevalence of CHD in patients with psoriasis was 9% (95% CI: 7.38–10.62) in the present analysis. The prevalence of CHD in the entire hospital-based population was 4.5% (95% CI: 4.44–4.69) in the present analysis, whereas the prevalence of CHD in general population estimated by the government data was 0.71% (95% CI: 0.66–0.76) which is calculated from the estimated total numbers of CHD patients (911,000) and the estimated numbers of total population (127,435,000) in Japan [47]. Thus, several sort of bias may exist in the hospital-based population in the present study. Although further population-based studies are required for generalization, we showed that psoriasis vulgaris is an independent associated factor for having CHD in the entire hospital-based population in the present study (Fig 1) and in patients with one or more disease codes surveyed after adjustment of age and sex (Table B in S1 File).

### Study Limitations

There were several limitations in the study. First, our study did not consider patients’ smoking status or blood tests. Smoking is a risk factor of psoriasis vulgaris [13]. Smoking may affect both CHD and psoriasis. Therefore, smoking would be an important factor. However, it was difficult to determine the smoking habits of all psoriasis patients because the EMR data were retrospective and disease-specific. In addition, since the data of the EMR of the total patients (113,065) was too large to be processed and the total number of patients was collected from the medical accounting system instead, the age and sex of the entire cohort were unknown. It is possible that other unknown confounding factors, including body weight and genetic backgrounds, affected the result. Lack of these data might lead to an inadequate adjustment. In addition, our study population did not represent the general Japanese population. Second, diagnostic codes consistent with the diseases may have included registered codes acceptable to the Japanese health care insurance system. There is a possibility that we overestimated or underestimated the prevalence of these diseases. Third, our study did not demonstrate a temporal relationship or dose-responsiveness. Finally, the CI of psoriasis was relatively broad (95% CI: 1.01–1.58). Therefore, we could not conclude that psoriasis is a risk factor of CHD. Patients with a longer duration of psoriasis vulgaris (defined as >8 years) tended to have CHD [17]. Psoriasis disease characteristics and medications may also impact the clinical outcome of CHD.
in those with psoriasis [10, 48]. Substantial undertreatment of coronary risk factors is noted in patients with severe psoriasis by Danish nationwide registry [49]. It is controversial whether biological drugs for psoriasis vulgaris, e.g., TNF-α inhibitors and IL12/23 inhibitors, reduce the risk for cardiovascular events [50–52]. Further population-based studies that consider psoriasis characteristics/treatment, age, sex, smoking, etc. are required to generalize and verify that psoriasis is an independent risk factor for CHD in the Japanese population.

Conclusion
Psoriasis vulgaris was independently associated with CHD in a hospital-based population in Japan.

Supporting Information
S1 File. Analysis of patients who have at least one disease including CHD, hypertension, dyslipidemia, diabetes, and psoriasis. Characteristics (Table A) and a multivariate logistic regression analysis (Table B).

Author Contributions
Conceived and designed the experiments: MS TK MI. Analyzed the data: MS TK MF EN SM TI TH. Wrote the paper: MS TK. Made critical revisions to the manuscript and approved the final version: TK MI.

References
1. Okada Y, Han B, Tsoi LC, Stuart PE, Ellinghaus E, Tejasvi T, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am. J. Hum. Genet. 2014; 95: 162–172. doi: 10.1016/j.ajhg.2014.07.002 PMID: 25087609
2. Zhang X, Wei S, Yang S, Wang Z, Zhang A, He P, et al. HLA-DQA1 and DQB1 alleles are associated with genetic susceptibility to psoriasis vulgaris in Chinese Han. Int. J. Dermatol. 2004; 43: 181–187. PMID: 15009387
3. Qi M, Huang X, Zhou L, Zhang J. Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis. DNA Cell Biol. 2014; 33: 234–244. doi: 10.1089/dna.2013.2252 PMID: 24678886
4. McMichael AJ, Vachiramon V, Guzmán-Sánchez DA, Carnacho F. Psoriasis in African-Americans: a caregivers’ survey. J. Drugs Dermatol. 2012; 11: 478–482. PMID: 22453585
5. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J. Am. Acad. Dermatol. 2014; 70: 512–516. doi: 10.1016/j.jaad.2013.11.013 PMID: 24388724
6. Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015; 5: e006450. doi: 10.1136/bmjopen-2014-006450 PMID: 25588781
7. Gelfand JM, Weinstein R, Porter SB, Neumann AL, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom—a population-based study. Arch. Dermatol. 2005; 141: 1537–1541. PMID: 16365254
8. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults—results from NHANES 2003–2004. J. Am. Acad. Dermatol. 2009; 60: 218–224. doi: 10.1016/j.jaad.2008.09.022 PMID: 19022533
9. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated Comorbidities (IMPACT) project team. Global epidemiology of psoriasis—a systematic review of incidence and prevalence. J. Invest. Dermatol. 2013; 133: 377–385. doi: 10.1038/jid.2012.339 PMID: 23014338
10. Tablazon IL, Al-Dabagh A, Davis SA, Feldman SR. Risk of cardiovascular disorders in psoriasis patients: current and future. Am. J. Clin. Dermatol. 2013; 14; 1–7. doi: 10.1007/s40257-012-0005-5 PMID: 23329076
11. Pietrzak A, Bartosińska J, Chodorowska G, Szepietowski JC, Paluszkiewicz P, Schwartz RA. Cardiovascular aspects of psoriasis: an updated review. Int. J. Dermatol. 2013; 52: 153–162. doi: 10.1111/j.1365-4632.2012.05584.x PMID: 23347301

12. Maradit-Kremers H, Dierkhising RA, Crowson CS, Icen M, Ernste FC, McEvoy MT. Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int. J. Dermatol. 2013; 52: 32–40. doi: 10.1111/j.1365-4632.2011.05430.x PMID: 23278607

13. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch. Dermatol. 2007; 143: 1559–1565. PMID: 18087008

14. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch. Intern. Med. 2007; 167: 1670–1675. PMID: 17698691

15. Wu S, Han J, Li WQ, Qureshi AA. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014; 150: 957–963. doi: 10.1001/jamadermatol.2013.9957 PMID: 24990147

16. Gelfand JM, Neumann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296: 1735–1741. PMID: 17032986

17. Armstrong AW, Harskamp CT, Ledo L, Rogers JH, Armstrong EJ. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am. J. Cardiol. 2012; 109: 976–980. doi: 10.1016/j.amjcard.2011.10.025 PMID: 22221950

18. Mahiques-Santos L, Soriano-Navarro CJ, Perez-Pastor G, Tomas-Cabedo G, Pitarch-Bort G, Valcuende-Cavero F. Psoriasis and ischemic coronary artery disease. Actas Dermosifiliogr. 2015; 106: 112–116. doi: 10.1016/j.ad.2014.08.002 PMID: 25304822

19. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007; 156: 271–276. PMID: 17223866

20. Ahlehoff O, Gislon GH, Jørgensen CH, Lindhardsen J, Charløt M, Olesen JB, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J. 2012; 33: 2054–2064. doi: 10.1093/eurheartj/ehr285 PMID: 21840930

21. Ahlehoff O, Gislon GH, Lindhardsen J, Charløt MG, Jørgensen CH, Olesen JB, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One. 2011; 6: e18125. doi: 10.1371/journal.pone.0018125 PMID: 21464995

22. Ahlehoff O, Gislon GH, Charløt M, Jørgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011; 270: 147–157. doi: 10.1111/j.1365-2796.2010.02310.x PMID: 21114692

23. Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014; 130: 837–844. doi: 10.1161/CIRCULATIONAHA.114.009990 PMID: 24970784

24. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008; 159: 895–902. doi: 10.1111/j.1365-2133.2008.08707.x PMID: 18616777

25. Mehta NN, Azfar RS, Shin DB, Neumann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010; 31: 1000–1006. doi: 10.1093/eurheartj/ehr567 PMID: 20037179

26. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009; 160: 1048–1056. doi: 10.1111/j.1365-2133.2008.09020.x PMID: 19210501

27. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2010; 130: 962–967. doi: 10.1038/jid.2009.321 PMID: 19812600

28. Stern RS, Huijbregts A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol. 2011; 131: 1159–1166 doi: 10.1038/ jid.2010.399 PMID: 21248765

29. Dowlatshahi EA, Kavoussi M, Nijsten T, Ikram MA, Hofman A, Franco OH, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol. 2013; 133: 2347–2354. doi: 10.1038/jid.2013.131 PMID: 23492918

30. Parisi R, Rutter MK, Lunt M, Young HS, Symmons DP, Griffiths CE, et al. Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. J Invest Dermatol. 2015; 135: 2189–2197. doi: 10.1038/jid.2015.87 PMID: 25742120

31. Ogdie A, Troxel AB, Mehta NN, Gelfand JM. Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3. J Invest Dermatol. 2015; 135: 2148–2450. doi: 10.1038/jid.2015.218 PMID: 26269404
32. Jain S, Kaur IR, Das S, Bhattacharya SN, Singh A. T helper 1 to T helper 2 shift in cytokine expression: an autoregulatory process in superantigen-associated psoriasis progression? J. Med. Microbiol. 2009; 58: 180–184. doi: 10.1099/jmm.0.003939-0 PMID: 19141734

33. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 2004; 113: 1664–1675. PMID: 15199399

34. Mattozzi C, Salvi M, D’Epiro S, Giancristofo S, Macaluso L, Luci C, et al. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature. Dermatology. 2013; 227: 134–145. doi: 10.1159/000353398 PMID: 24051528

35. Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol. Online J. 2012; 18: 1.

36. Furuhashi T, Saito C, Torii K, Nishida E, Yamazaki S, Morita A. Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis. PLoS One. 2013; 8: e54895. doi: 10.1371/journal.pone.0054895 PMID: 23365685

37. Di Meglio P, Di Cesare A, Lagger U, Chu CC, Villanova F, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One. 2011; 6: e17160. doi: 10.1371/journal.pone.0011760 PMID: 21364948

38. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology. 2007; 148: 3356–3363. PMID: 17446186

39. Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr. Rheumatol. Rep. 2012; 14: 343–348. doi: 10.1007/s11926-012-0260-8 PMID: 22562431

40. Ogdie A, Yu Y, Haynes K, Love TJ, Malilha S, Jiayu Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015; 74: 326–332.

41. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013; 133: 2340–2346. doi: 10.1038/jid.2013.149 PMID: 23528816

42. Cohen AD, Kagen M, Friger M, Halevy S. Calcium channel blockers intake and psoriasis: a case-control study. Acta. Derm. Venereol. 2001; 81: 347–349. PMID: 11800142

43. Salihbegovic EM, Hadzigrahic N, Suljagic E, Kurtalic N, Hadzic J, Zejcirovic A, et al. Psoriasis and dyslipidemia. Mater. Sociomed. 2015; 27: 15–17. doi: 10.5455/msm.2014.27.15-17 PMID: 25870525

44. Kawano H, Soejima H, Kojima S, Kitagawa A, Ogawa H; Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Sex differences of risk factors for acute myocardial infarction in Japanese patients. Circ J 2006; 70: 513–517. PMID: 16636482

45. Iso H, Sato S, Kitamura A, Imano H, Kiyama M, Yamagishi K, et al. Metabolic syndrome and the risk of cardiovascular mortality in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. JAMA. 2011; 306: 864–871. doi: 10.1001/jama.2011.1211 PMID: 21862748

46. Mehta NN, Azfar RS, Shin DB, Neumann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the Danish nationwide registries. PLoS One. 2012; 7: e42346. doi:10.1371/journal.pone.0042346 PMID: 22919025

47. Jain S, Kaur IR, Das S, Bhattacharya SN, Singh A. T helper 1 to T helper 2 shift in cytokine expression: an autoregulatory process in superantigen-associated psoriasis progression? J. Med. Microbiol. 2009; 58: 180–184. doi: 10.1099/jmm.0.003939-0 PMID: 19141734

48. Mehta NN, Azfar RS, Shin DB, Neumann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur. Heart J. 2010; 31: 1000–1006. doi: 10.1093/eurheartj/ehp567 PMID: 20037179

49. Salihbegovic EM, Hadzigrahic N, Suljagic E, Kurtalic N, Hadzic J, Zejcirovic A, et al. Psoriasis and dyslipidemia. Mater. Sociomed. 2015; 27: 15–17. doi: 10.5455/msm.2014.27.15-17 PMID: 25870525

50. Ryan C, Leonard CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011; 306: 864–871. doi: 10.1001/jama.2011.1211 PMID: 21862748

51. Tzéllos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 2013; 27: 622–627. doi: 10.1111/j.1468-3083.2012.04500.x PMID: 22404103